F2 and poliomyelitis: The immunogenicity results indicated that ≥ 95.7% of infants in the co-administered group and ≥ 92.8% in the staggered group were seroprotected for anti-D, anti-T and anti-polio 1, 2 and 3, and were seropositive for anti-PT and anti-FHA antibodies.